Business Context and Reporting Period
This summary covers the Form 10-Q for Point Capital, Inc. (not Silo Pharma, Inc., as indicated in the metadata request) for the quarter and nine months ended September 30, 2016. Point Capital is a closed-end, non-diversified Business Development Company (BDC) and Regulated Investment Company (RIC) focused on investing in small and mid-cap U.S. companies via equity, warrants, and convertible debt. The company reported 50,082,441 shares of common stock outstanding as of October 28, 2016.
Key Financial Metrics
| Metric | Sept 30, 2016 | Dec 31, 2015 |
|---|---|---|
| Total Assets | $1,438,800 | $2,450,236 |
| Investments at Fair Value | $843,848 | $1,691,518 |
| Cash and Cash Equivalents | $542,955 | $722,764 |
| Total Liabilities | $49,290 | $90,756 |
| Redeemable Preferred Stock | $400,000 | $400,000 |
| Total Net Assets | $989,510 | $1,959,480 |
| Net Asset Value (NAV) per Share | $0.02 | $0.04 |
Operating Results (Nine Months Ended Sept 30, 2016)
- Total Investment Income: $40,789 (Interest income: $40,789; Dividend income: $0).
- Total Operating Expenses: $367,618 (Significant increase in professional fees to $221,267).
- Net Investment Loss: $(326,829).
- Net Realized Gain on Investments: $23,400.
- Net Change in Unrealized Loss on Investments: $(666,541).
- Net Decrease in Net Assets from Operations: $(969,970).
Material Changes vs. Prior Period
- Portfolio Valuation Decline: The fair value of investments dropped 50% from $1.69 million to $0.84 million, driven primarily by a $666,541 unrealized loss. This was largely due to decreases in the value of warrants (~$313,000) and common/preferred shares (~$302,000).
- Expense Surge: Operating expenses for the nine-month period increased 91.6% year-over-year, primarily due to a 194.6% increase in professional fees (audit, legal, and consulting) and a 31.1% increase in compensation expenses.
- Liquidity Reduction: Cash and cash equivalents decreased by $179,809 (24.9%) due to operating cash outflows and investment purchases, partially offset by proceeds from investment sales.
- NAV Erosion: Net Asset Value per share halved from $0.04 to $0.02.
Outlook, Risks, and Contingencies
- Liquidity Risk: Management believes existing cash ($542,955) is sufficient for 12 months of operations. However, the company has no agreements to raise capital and may need to reduce investment scope or cease operations if additional funding is unavailable.
- Internal Control Deficiencies: The company disclosed that disclosure controls and procedures were ineffective. Material weaknesses include failure to timely recognize share issuance violations, lack of Investment Act experienced staff, lack of segregation of duties, and lack of control over investment valuation.
- Reporting Delays: The company admitted to filing delays for the 2015 annual report and Q1/Q2 2016 reports, placing it in breach of its agreement with Series A Preferred Stock holders, though no immediate default consequences were triggered.
- Portfolio Concentration: The portfolio is concentrated in non-controlled, non-affiliated investments in small-cap and private companies, many of which are illiquid or have no readily determinable market value (Level 3 assets).
Investor Verification Checklist
- Capital Adequacy: Verify if the company has secured new financing to sustain operations beyond the projected 12-month runway.
- Valuation Methodology: Scrutinize the fair value assumptions for Level 3 assets (approx. $457k of the portfolio), given the material weaknesses in valuation controls.
- Preferred Stock Status: Monitor the status of the $400,000 Series A Convertible Preferred Stock and any potential triggering events due to continued reporting delays.
- Expense Management: Assess the sustainability of the current expense ratio (22.32% of average net assets) relative to the shrinking asset base.
- Remediation Plan: Confirm progress on hiring compliance staff and implementing segregation of duties to address internal control failures.